Status:
COMPLETED
Effect of Selective COX-2 Inhibition on Ulcer Healing
Lead Sponsor:
Chinese University of Hong Kong
Conditions:
Arthritis
Gastric Ulcer
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
The purpose of this study is to compare the effect of Famotidine plus a COX-2 inhibitor (celecoxib) with Famotidine plus dologesics in ulcer healing in arthritis patients.
Detailed Description
For many years the integrity of the stomach mucosal barrier is thought to be maintained by mucosal prostaglandins (PG) synthesized by COX-1. However, the notion that COX-1 protects the stomach and COX...
Eligibility Criteria
Inclusion
- Gastric ulcers confirmed by endoscopy
- Stop taking NSAIDs for 1 week prior to endoscopy
- Age 18
- H. pylori negative
- Informed written consent
Exclusion
- Actively bleeding ulcers
- Ulcers showing dysplasia or malignancy
- Renal failure (serum creatinine \>200umol/l)
- Previous gastric surgery
- Moribund or terminal malignancy
- Concomitant use of proton pump inhibitor, misoprostol, aspirin, steroid or anticoagulant
Key Trial Info
Start Date :
February 1 2001
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 12 2017
Estimated Enrollment :
200 Patients enrolled
Trial Details
Trial ID
NCT00153673
Start Date
February 1 2001
End Date
April 12 2017
Last Update
April 21 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Endoscopy Center, Prince of Wales Hospital
Hong Kong, China